2020 Chinese guidelines for the diagnosis and treatment of systemic lupus erythematosus
Mengtao Li, Yan Zhao, Zhiyi Zhang, Cibo Huang, Yi Liu, Jieruo Gu, Xiao Zhang, Huji Xu, Xiaofeng Li, Lijun Wu, Yijun Song, Xuemei Li, Hongzhong Jin, Junqiang Lei, Yaolong Chen, Xiaofeng Zeng
Abstract
Systemic lupus erythematosus (SLE) is a heterogeneous autoimmune disease that represents a prodigious challenge of diagnosis and treatment. In 2019, under the leadership of the Chinese Rheumatology Association, a multidisciplinary guideline development group was established to develop an evidence-based diagnosis and treatment guideline for patients with SLE in PR China. The Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach was used to evaluate the quality of evidence and the strength of recommendations. The guideline was reported following the Reporting Items for Practice Guidelines in Healthcare (RIGHT) checklist. In this guideline, we provided recommendations for SLE classification criteria, disease activity monitoring and assessment, medication administration and considerations for SLE patients with organs and systems involved, and management of special populations such as SLE patients in the setting of pregnancy. This guideline serves as an evidence-based tool for Chinese clinicians to diagnose and treat patients with SLE.